![]() | This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
|
![]() | Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Fluticasone furoate/vilanterol.
|
So moved here.
Extended content
|
---|
Fluticasone Furoate, an inhaled corticosteroid, has been shown to have a potent pharmacological profile on a respiratory inflammation disease in animal studies. It was described as being safe and effective. [1] Additionally, inhaled corticosteroids have been shown to have a beneficial risk/benefit ratio in patients over multiple studies, with that caveat that chronic use be monitored. [2] They were also shown to have a favorable risk/benefit ratio in the treatment of patients with Chronic Obstructive Pulmonary Disorder (COPD). [3] Similarly, Vilanterol was shown to be a potent, selective ß2 Adrenoceptor agonist with a long duration of action. [4] Long-acting ß2 Adrenoceptor agonists were shown to be safe for use in patients with stable moderate-to-severe COPD in another systematic review. [5] |
Doc James ( talk · contribs · email) 19:11, 20 November 2016 (UTC)
References
![]() | This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
|
![]() | Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Fluticasone furoate/vilanterol.
|
So moved here.
Extended content
|
---|
Fluticasone Furoate, an inhaled corticosteroid, has been shown to have a potent pharmacological profile on a respiratory inflammation disease in animal studies. It was described as being safe and effective. [1] Additionally, inhaled corticosteroids have been shown to have a beneficial risk/benefit ratio in patients over multiple studies, with that caveat that chronic use be monitored. [2] They were also shown to have a favorable risk/benefit ratio in the treatment of patients with Chronic Obstructive Pulmonary Disorder (COPD). [3] Similarly, Vilanterol was shown to be a potent, selective ß2 Adrenoceptor agonist with a long duration of action. [4] Long-acting ß2 Adrenoceptor agonists were shown to be safe for use in patients with stable moderate-to-severe COPD in another systematic review. [5] |
Doc James ( talk · contribs · email) 19:11, 20 November 2016 (UTC)
References